Postdoctoral position in Bioinformatics and Cancer Genomics at the IMP in Vienna A postdoctoral position localized at the IMP in collaboration with Boehringer Ingelheim Oncology in Vienna is available immediately. Research: The person will work closely with scientists at the IMP and Boehringer Ingelheim to implement analysis pipelines for next generation sequencing projects in the area of cancer genomics. In-house generated data as well as selected public domain data sets should be integrated with an already existing large data collection. A strong focus will be the comprehensive characterization of cancer cell lines with the aim to explain and understand genotype-dependent differential responses to novel targeted therapies. Requirements: The successful candidate should have a PhD degree in bioinformatics, molecular biology or in a related discipline with a proven record in genome/transcriptome sequence analysis, preferentially in the context of NGS. A profound understanding of cancer genomics/biology and the ability to translate and communicate results is highly desired. The candidate should be comfortable in handling very large datasets and be able to identify and implement computationally efficient data processing strategies in a linux environment. Terms and locale: The position is initially for two years, location Vienna, Austria. Institution Background: The Research Institute of Molecular Pathology (IMP) is a basic biomedical research institute sponsored largely by Boehringer Ingelheim, as well as research grants from national and international funding agencies. Boehringer Ingelheim is a research-driven international pharmaceutical company with around 40.000 employees world-wide. The research site in Vienna is solely dedicated to cancer research. Links: http://www.imp.ac.at/ http://www.boehringer-ingelheim.com/corporate/research/centres.asp#3 Contact: Interested candidates should contact Christian.Haslinger at boehringer-ingelheim.com along with copies of their CV, publication list and names of reference persons.